3,3,20,20-双(亚乙二氧基)- 5α,17α-二羟基-11β-[4-(N,N-二甲基氨基)-苯基]-19-去甲孕甾-9(11)-烯

3,3,3,20,20-Bis(ethylene-dioxy) -5alpha,17alpha-dihydroxy-11beta-[4-(N, N-dimethylamino)-phenyl]-19-norpregna-9(11)-ene;

四川更新日期：2025-10-09

成都伊诺达博医药科技有限公司

VIP14年

联系人：包经理

电话：028-85105512拨打

手机：17802830247 拨打

邮箱：baozuqiang@d-innovation.com

产品详情:

中文名称：: 3,3,20,20-双(亚乙二氧基)- 5α,17α-二羟基-11β-[4-(N,N-二甲基氨基)-苯基]-19-去甲孕甾-9(11)-烯

英文名称：: 3,3,3,20,20-Bis(ethylene-dioxy) -5alpha,17alpha-dihydroxy-11beta-[4-(N, N-dimethylamino)-phenyl]-19-norpregna-9(11)-ene;

CAS号：: 126690-41-3

醋酸优力司特中间体、醋酸乌利司他中间体126690-41-3

中文名称：3,3,20,20-双(亚乙二氧基)- 5α,17α-二羟基-11β-[4-(N,N-二甲基氨基)-苯基]-19-去甲孕甾-9(11)-烯

英文名称：3,3,3,20,20-Bis(ethylene-dioxy) -5alpha,17alpha-dihydroxy-11beta-[4-(N, N-dimethylamino)-phenyl]-19-norpregna-9(11)-ene;

CAS 号：126690-41-3

含量标准：98% HPLC

醋酸优力司特；醋酸乌利司他；126690-41-3；CAS 126690-41-3

We are offering three key services for new drug application, a. Mature(repeatable) pilot process with independent intellectual property rights; b. High purity sample designed for pharm companies; c. Impurity study. Our main products are Ulipristal acetate intermediates &impurities; Alogliptin benzoate intermediates, impurities &metabolin; Ezetimibe intermediates &impurities; Abiraterone Acetate; Dienogest; Tenofovir disoproxil fumarate & its intermediates; Bortezomib; Cabazitaxel; Lacosamide intermediates; Minodronic acid.

成立日期	(19年)
注册资本	1500万元人民币
员工人数	100-500人
年营业额	￥ 5000万-1亿
经营模式	工厂,工厂
主营行业	医药中间体,医药中间体,原料药,原料药